>> thank you, geoff. and good afternoon, everybody. u.s. representative christopher collins sat on innate's board of directors for a period of more than three years, spanning the run-up to the drug trial announcement in mid-2017. collins himself was the company's largest shareholder. in or about the summer of 2017, a drug designed to treat a debilitating form of multiple sclerosis had entered the late stages of a phase ii clinical trial. this drug, mis-416, was the only viable drug in the pipeline for innate. this is significant in that the company's value was nearly completely wrapped up in the success of the clinical trial and a subsequent phase iii trial. on the evening of june 22nd, 2017, collins received an e-mail informing him that mis-416 had failed its clinical trial. electronic records indicate his initial shock at having received the news.
Related Keywords
Geoff Berman , Board Of Directors , Us , Yinnate , Christopher Collins Sat , Everybody , Drug Trial Announcement , Run Up , 2017 Collins , Three , 2017 , Congressman Collins , Insurance Company , Drug , Shareholder , Phase Ii Clinical Trial , Form , Multiple Sclerosis , Stages , Clinical Trial , Mis 416 , Value , Phase Iii Trial , Pipeline , Success , 416 , News , E Mail , Evening , Records , Shock , June 22nd 2017 , 22 ,
comparemela.com © 2020. All Rights Reserved.